Medicxi announces the closing of its first €200 million secondary fund, led by Pantheon with co-lead LGT Capital Partners
Category: Transactions Year: 2020
23 September 2020
Medicxi, the leading European life sciences investment firm, announces the closing of Medicxi Secondary 1 (MS1) in connection with the completion of an “Exit & Reinvest” type of structured secondary transaction, which is unprecedented in the biotechnology industry.
Campbell Luytens acted as financial advisor.
The interests in six clinical and preclinical stage companies held by Index Ventures Life VI, a dedicated life sciences fund advised by Medicxi, were acquired by a newly formed fund managed by Medicxi, called MS1. The new fund has been anchored by leading secondary investor, Pantheon (London), with LGT Private Equity (Pfaeffikon, Switzerland) as co-lead investor.
